Thiazolidinediones
May 20th, 2009
Thiazolidinediones are used to treat diabetes type 2.
Thiazolidinediones (TZDs) bind to the PPAR gamma (peroxisome proliferator-activated receptors gamma) receptor. When the PPAR gamma is bound by a TZD, transcription of several genes is activated. PPAR Gamma activation leads to decreased insulin resistance, modified adipocyte differentiation, decreased leptin levels, and angiogenesis is inhibited.
Recent studies indicate that Thiazolidinedione use may increase the risk of heart failure and myocardial infarction.
| Medication Name | Generic Available | Discount Programs |
| Rosiglitazone (Avandia, Avandamet*, Avandaryl**) | No | The Avandia patent expires in 2012 |
| Pioglitazone (Actos, Actoplus Met*, Duetact**) | No | The Actos patent expires in 2011 |
*Includes metformin
**Includes glimepiride
